April 23 (UPI) -- On Thursday, President Donald Trump announced a new drug price deal with Regeneron, the latest to agree to the "most favored nation" price policy the White House has pushed since last year.
The price deals involve voluntary price cuts by manufacturers for drugs sold to the public and the government through the TrumpRx website. In return, the manufacturers get breaks on Trump's tariffs and other perks.
In addition, Regeneron also announced Thursday that the Federal Food and Drug Administration has approved Otarmeni, a gene therapy for genetic hearing loss. The company said the therapy would be available free in the United States.
The company is the last of the 17 the administration sought for the price policy, but officials said that more will follow. Smaller companies may also look to make deals.
Related
